Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/05/2019 | 04:01am EST
The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

(This story corrects a typo in the first paragraph)

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
12/05AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatmen..
RE
12/05ASTRAZENECA : Lynparza approved in China for 1L BRCAm ovarian
AQ
12/03ASTRAZENECA : Sells Seroquel Rights to Cheplapharm
DJ
12/03ASTRAZENECA : divests rights to Seroquel and Seroquel XR in the US and Canada
PU
12/03ASTRAZENECA DIVESTS SEROQUEL RIGHTS : US and Canada
AQ
11/30China to use drug bulk-buy program to close price gap
RE
11/29AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer
RE
11/29ASTRAZENECA : Gets US License for Imfinzi Lung-Cancer Drug
DJ
11/29ASTRAZENECA : Imfinzi granted FDA Priority Review for SCLC
AQ
11/28LONDON STOCK EXCHANGE : FTSE slips on ex-div trading, U.S.-China trade doubts
RE
More news
Financials (USD)
Sales 2019 24 459 M
EBIT 2019 6 603 M
Net income 2019 1 976 M
Debt 2019 11 731 M
Yield 2019 3,87%
P/E ratio 2019 43,3x
P/E ratio 2020 28,9x
EV / Sales2019 4,37x
EV / Sales2020 3,97x
Capitalization 95 219 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 101,31  $
Last Close Price 72,58  $
Spread / Highest target 86,1%
Spread / Average Target 39,6%
Spread / Lowest Target -2,35%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA23.09%124 710
JOHNSON & JOHNSON8.14%367 304
ROCHE HOLDING AG25.10%263 429
MERCK AND COMPANY16.15%225 956
PFIZER-12.88%210 463
NOVARTIS21.74%207 450